PuraPharm Corporation Ltd is an investment holding company principally engaged in the concentrated Chinese medicine granule (CCMG) businesses. The Company operates through five business segments. The China CCMG segment is mainly engaged in the production and sales of CCMG products in China. The Hong Kong CCMG segment is mainly engaged in the sales of CCMG products, excluding the sales through self-operated clinics in Hong Kong. The Chinese Healthcare Products segment is mainly engaged in the production and sales of healthcare products in Hong Kong and China. The Clinics segment is mainly engaged in the provision of Chinese medical diagnostic services and sales of CCMG products through self-operated clinics. The Plantation segment is mainly engaged in the plantation and trading of raw Chinese herbs, and the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces.

Employees

441

Sector

Healthcare Facilities & Services

More about the company

Quotes

Date	Price	Change	Volume
03/08/26	HK$0.2850	+1.79%	211,000
31/07/26	HK$0.2800	+1.82%	41,000
30/07/26	HK$0.2750	-3.51%	308,000
29/07/26	HK$0.2850	-1.72%	56,500
28/07/26	HK$0.2900	0.00%	168,000

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 11:08:12 03/08/2026 +03			5-day change	1st Jan Change
0.2850 ^HKD	+1.79%		0.00%	-19.72%

06-26	Purapharm Corporation Limited Announces Resignation of Prof. Tsui Lap Chee from Independent Non-Executive Director and Board Committees, Effective June 25, 2026	CI
04-27	PuraPharm Corporation Limited Announces Appointment of Lee Stephen as Independent Non-Executive Director, Effective April 27, 2026	CI

Market Cap	152M 19.45M 16.9M 15.78M 14.48M 27.31M 1.85B 27.79M 186M 72.86M 924M 73.04M 71.42M 3.05B	P/E 2024	-6.13x	P/E 2025	-4.22x
Enterprise Value	468M 59.64M 51.84M 48.4M 44.43M 83.77M 5.69B 85.23M 571M 223M 2.84B 224M 219M 9.35B	EV / Sales 2024	1.42x	EV / Sales 2025	1.5x
Free-Float	34.74%	Yield 2024 *	-	Yield 2025	-

06-26	Purapharm Corporation Limited Announces Resignation of Prof. Tsui Lap Chee from Independent Non-Executive Director and Board Committees, Effective June 25, 2026	CI
04-27	PuraPharm Corporation Limited Announces Appointment of Lee Stephen as Independent Non-Executive Director, Effective April 27, 2026	CI
04-23	PuraPharm Corporation Limited Auditor Raises 'Going Concern' Doubt	CI
03-26	PuraPharm's Loss Narrows Slightly in 2025	MT
03-26	PuraPharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-24	PuraPharm Completes HK$20 Million Convertible Bond Issue	MT
03-23	PuraPharm Corporation Limited announced that it has received HKD 20 million in funding from Protoss Global Opportunities Fund	CI
02-26	Purapharm Corp to issue convertible bonds with principal amount of HK$20 mln	RE
02-26	PuraPharm Sells HK$20 Million Convertible Bonds	MT
02-26	PuraPharm Corporation Limited announced that it expects to receive HKD 20 million in funding from Protoss Global Opportunities Fund	CI
30/10/25	PuraPharm Corporation Limited Announces Appointment of Dong Zimeng as Non-Executive Director, Effective October 30, 2025	CI
02/10/25	PuraPharm to Vote Oct. 24 on Rheumatoid Arthritis Drug License, Share Issue Agreements	MT
29/08/25	Purapharm Corporation Limited Appoints Hung Ting On, John as Independent Non-Executive Director, the Chairman of the Audit Committee of the Board, the Member of the Remuneration Committee of the Board and Member of Nomination Committee of the Board, Effective August 29, 2025	CI

29/07/21	PuraPharm : RESIGNATION OF CHIEF FINANCIAL OFFICER, CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE	PU
21/04/21	PuraPharm : (I) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (II) PROPOSED GRANT OF GENERAL MANDATES TO BUY BACK SHARES AND ISSUE NEW SHARES; (III) PROPOSED REFRESHMENT OF SCHEME MANDATE LIMIT UNDER THE SHARE OPTION SCHEME; (IV) PROPOSED CHANGE OF COMPANY NAME; (V) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION OF THE COMPANY; AND NOTICE OF ANNUAL GENERAL MEETING	PU
25/03/21	PuraPharm : EXTENSION OF LONG STOP DATE FOR CONNECTED TRANSACTION	PU
22/09/20	PuraPharm : Interim report 2020	PU
25/08/20	PuraPharm : CONNECTED TRANSACTION - ACQUISITION OF INTELLECTUAL PROPERTIES	PU

PuraPharm Corporation Limited Stock

Stocks

1498

KYG7306Y1044

Healthcare Facilities & Services

Valuation: PuraPharm Corporation Limited

Chart: PuraPharm Corporation Limited

Latest news : PuraPharm Corporation Limited

Press Releases: PuraPharm Corporation Limited

Quotes and Performance

Course Extremes

Managers and Directors: PuraPharm Corporation Limited

Latest insider transactions

Hospitals, Clinics & Primary Care Services

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	+1.79%
Current month	+1.79%
1 month	-5.00%
3 months	-1.72%
6 months	-14.93%
Current year	-19.72%

1 week	0.27	0.3
1 month	0.27	0.3
Current year	0.27	0.38
1 year	0.27	0.48
3 years	0.27	1.26
5 years	0.27	2
10 years	0.27	4.39

Manager	Title	Age	Since
Yu Ling Chan CEO	Chief Executive Officer	65	05/05/1998
Wing Hung Lam DFI	Director of Finance/CFO	38	01/01/2024
Hao Claire IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Yu Ling Chan CHM	Chairman	65	05/05/1998
Yee Wai Man BRD	Director/Board Member	60	02/12/2011
Lim Kin Leung BRD	Director/Board Member	72	12/06/2015

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/27/22 A	Yu Ling Chan	Other	Chief Executive Officer	30,000	0.0076%
7/27/22 A	Chan Yu Ling Abraham Family	Other		30,000	0.0076%
5/3/22 A	Yu Ling Chan	Other	Chief Executive Officer	77,500	0.0196%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PURAPHARM CORPORATION LIMITED	+1.79%	0.00%	-39.36%	-69.02%	19.11M
IHH HEALTHCARE	-0.60%	0.00%	+24.25%	+39.26%	18.06B
APOLLO HOSPITALS ENTERPRISE LIMITED	-1.53%	+0.16%	+19.98%	+76.51%	13.49B
AIER EYE HOSPITAL GROUP CO., LTD.	-0.22%	+7.09%	-29.55%	-53.47%	12.46B
ENCOMPASS HEALTH CORPORATION	+1.27%	-1.48%	+2.47%	+58.97%	11.02B
THE ENSIGN GROUP, INC.	-0.00%	+0.12%	+15.07%	+81.00%	10.3B
BANGKOK DUSIT MEDICAL SERVICES	+2.08%	+3.70%	-6.22%	-30.62%	9.13B
FORTIS HEALTHCARE LIMITED	-0.53%	-0.92%	+9.40%	+180.60%	7.47B
RAMSAY HEALTH CARE LIMITED	-1.04%	+3.74%	+15.44%	-25.00%	7.16B
PURE HEALTH HOLDING	+2.21%	+4.52%	-23.00%	-	6.84B
Average	+0.29%	+1.74%	-1.15%	+28.69%	9.59B
Weighted average by Cap.	-0.03%	+1.99%	+5.08%	+38.71%

	2024	2025
Net sales	382M 48.72M 42.35M 39.53M 36.29M 68.43M 4.64B 69.63M 466M 183M 2.32B 183M 179M 7.64B	336M 42.86M 37.25M 34.78M 31.93M 60.2M 4.09B 61.25M 410M 161M 2.04B 161M 157M 6.72B
Net income	-35.44M -4.52M -3.93M -3.67M -3.37M -6.35M -431M -6.46M -43.24M -16.93M -215M -16.97M -16.6M -708M	-35.22M -4.49M -3.9M -3.64M -3.35M -6.31M -428M -6.42M -42.97M -16.83M -213M -16.87M -16.5M -704M
Net Debt	327M 41.68M 36.22M 33.82M 31.05M 58.54M 3.97B 59.56M 399M 156M 1.98B 157M 153M 6.53B	315M 40.2M 34.94M 32.62M 29.94M 56.46M 3.83B 57.44M 385M 151M 1.91B 151M 148M 6.3B